EUVIMEDEUVIMED entdecken
Multizentrische Studie

Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD

Sophie Vieujean iD, James O Lindsay, Ferdinando D'Amico, Vineet Ahuja iD, Mark S Silverberg, Ajit Sood iD, Jesus K Yamamoto-Furusho iD, Masakazu Nagahori, Mamoru Watanabe, Ioannis E Koutroubakis, Kalliopi Foteinogiannopoulou iD, Irit Avni Biron iD und 12 weitere

Journal of Crohn's and Colitis · 2024

DOI: 10.1093/ecco-jcc/jjad180 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Crohn's and Colitis, 2024. Verfasst von Sophie Vieujean und 23 weiteren Autor:innen. Beteiligte Einrichtung: Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Liège, Liège, Belgium. Hauptthemen laut MEDLINE: Patient Selection, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Fund for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recruitment for randomized controlled trials [RCTs] in inflammatory bowel diseases [IBD] has substantially dropped over time. This study aimed to assess reasons why IBD patients are not included in sponsored multicentre phase IIb–III RCTs.

Methods

All IOIBD members [n = 58] were invited to participate. We divided barriers to participation as follows: [1] reasons patients with active IBD were not deemed appropriate for an RCT; [2] reasons qualified patients did not wish to participate; and [3] reasons for screen failure [SF] in patients agreeing to participate. We assess these in a 4-week prospective study including, consecutively, all patients with symptomatic disease for whom a treatment change was required. In addition, we performed a 6-month retrospective study to further evaluate reasons for SF.

Results

A total of 106 patients (60 male [56.6%], 63 Crohn’s disease [CD] [59.4%]), from ten centres across the world, were included in the prospective study. An RCT has not been proposed to 65 of them [mainly due to eligibility criteria]. Of the 41 patients to whom an RCT was offered, eight refused [mainly due to reluctance to receive placebo] and 28 agreed to participate. Among these 28 patients, five failed their screening and 23 were finally included in an RCT. A total of 107 patients (61 male [57%], 67 CD [62.6%]), from 13 centres worldwide, were included in our retrospective study of SFs. The main reason was insufficient disease activity.

Conclusion

This first multicentre study analysing reasons for non-enrolment in IBD RCTs shows that we lose patients at each step. Eligibility criteria, the risk of placebo assignment, and insufficient disease activity were part of the main barriers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient SelectionInflammatory Bowel DiseasesHumansMaleFemaleProspective StudiesAdultRetrospective StudiesRandomized Controlled Trials as TopicMiddle AgedCrohn Disease

Stichwörter der Autor:innen

Inflammatory bowel diseasenon-enrolmentrandomized controlled trialsscreen failure

Autor:innen und Institutionen

  • Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Liège, Liège, Belgium.
  • Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK; Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London, UK.
  • Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
  • Toronto Immune and Digestive Health Institute, Toronto, Canada.

ORCID-Profile: Sophie Vieujean, Vineet Ahuja, Ajit Sood, Jesus K Yamamoto-Furusho, Kalliopi Foteinogiannopoulou, Irit Avni Biron, Corey Siegel, Walter Reinisch, Silvio Danese

Förderung

  • National Fund for Scientific Research

Zitieren

APA

Vieujean, S., Lindsay, J. O., D'Amico, F., Ahuja, V., Silverberg, M. S., Sood, A., Yamamoto-Furusho, J. K., Nagahori, M., Watanabe, M., Koutroubakis, I. E., Foteinogiannopoulou, K., Avni Biron, I., Walsh, A., Outtier, A., Nordestgaard, R. L. M., Abreu, M. T., Dubinsky, M., Siegel, C., Louis, E., …, & Peyrin-Biroulet, L. (2024). Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjad180

Vancouver

Vieujean S, Lindsay JO, D'Amico F, Ahuja V, Silverberg MS, Sood A, et al. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. Journal of Crohn's and Colitis. 2024. doi:10.1093/ecco-jcc/jjad180

BibTeX
@article{Vieujean2024,
  author = {Vieujean, Sophie and Lindsay, James O and D'Amico, Ferdinando and Ahuja, Vineet and Silverberg, Mark S and Sood, Ajit and Yamamoto-Furusho, Jesus K and Nagahori, Masakazu and Watanabe, Mamoru and Koutroubakis, Ioannis E and Foteinogiannopoulou, Kalliopi and Avni Biron, Irit and Walsh, Alissa and Outtier, An and Nordestgaard, Rie Louise Møller and Abreu, Maria T and Dubinsky, Marla and Siegel, Corey and Louis, Edouard and Dotan, Iris and Reinisch, Walter and Danese, Silvio and Rubin, David T and Peyrin-Biroulet, Laurent},
  title = {Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD},
  journal = {Journal of Crohn's and Colitis},
  year = {2024},
  doi = {10.1093/ecco-jcc/jjad180}
}
Kostenlos starten →